Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

Shots:

  • Vertex acquires Semma Therapeutics, in all cash transaction making a total deal value $950M and Semma will operate as a subsidiary of Vertex. The transaction is expected to be completed in Q4’19
  • The acquisition targets Semma’s unique investigational approach of combining the production of Islets of Langerhans cells in the pancreas with a delivery system to restore insulin secretion in T1D patients
  • Islet cell transplantation provides physiologic regulation of blood glucose, thus prevent both hyperglycemic and hypoglycemic episodes associated with the current SOC i.e, insulin injection & pumps

Click here to­ read full press release/ article | Ref: Vertex | Image: Odessa American